Lorazepam Injection IP 2 mg/mL - LORZIN

LORZIN Injection is a sterile parenteral benzodiazepine solution containing Lorazepam IP 2 mg/mL, supplied as 10 x 2 mL ampoules by Dellwich Lifescience. It is primarily used for the emergency cessation of status epilepticus, acute psychiatric agitation, pre-anesthetic sedation, and severe alcohol withdrawal delirium.

Although Diazepam enters the brain rapidly, it quickly redistributes into body fat within 15 to 30 minutes, allowing seizures to recur. Lorazepam is less lipid-soluble; once inside brain tissue, it remains tightly bound to GABA_A receptors, providing therapeutic anticonvulsant control lasting 12 to 24 hours.

In adult status epilepticus, the standard intravenous dose is 4 mg (2 mL) administered slowly over 2 minutes (rate not exceeding 2 mg/min). If seizures continue after 10 to 15 minutes, an additional 4 mg dose may be administered under continuous respiratory monitoring.

LORZIN Injection should be diluted with an equal volume of compatible diluent (such as 0.9% Sodium Chloride or 5% Dextrose Injection) to reduce injection-site irritation. It must be injected slowly into a large vein, not exceeding 2 mg per minute.

Yes. When intravenous access cannot be rapidly secured (e.g., in violently agitated psychiatric patients or status epilepticus outside the ICU), undiluted LORZIN Injection can be administered by deep intramuscular injection into a large muscle mass like the gluteus maximus.

Following slow intravenous administration, anticonvulsant and sedative effects commence within 1 to 3 minutes. Following intramuscular injection, clinical onset of action occurs within 15 to 30 minutes, with peak plasma concentrations achieved in 60 to 90 minutes.

Because parenteral benzodiazepines can cause significant respiratory depression, hypotension, and airway compromise, bag-valve-mask resuscitation equipment, oxygen, and emergency airway support must be immediately accessible. Flumazenil should be available as a specific reversal agent.

LORZIN ampoules must be stored under refrigeration between 2°C and 8°C. Protect from light. Do not freeze. Discard any solution showing discoloration or visible particulates.

Administered 1 to 2 hours before surgery, LORZIN produces reliable anxiolysis, pre-operative calmness, and anterograde amnesia, preventing traumatic patient recall of induction and surgical events.

Yes. Due to its direct Phase II glucuronidation, Lorazepam does not place oxidative burden on the liver, making LORZIN Injection the preferred parenteral agent in patients with alcohol-related liver injury presenting with severe delirium tremens or withdrawal seizures.

LORZIN is supplied in boxes containing 10 amber glass ampoules of 2 mL each (2 mg/mL, 4 mg total Lorazepam per ampoule), labeled for IM/IV use.

Hospital purchase officers and institutional distributors can connect with our institutional sales desk at +91 99099 31992 or submit an enquiry through the form below for immediate quotations and batch COA.

Yes. Dellwich Lifescience provides turnkey contract manufacturing for sterile liquid injectables with WHO-GMP certification, complete stability testing records, and prompt pan-India dispatch from Ahmedabad.

Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with cold-chain logistics arrangements to ensure integrity during transport.